{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":31,"n_cols":5,"rows_kept":31,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[3,2,3,3],[4,2,4,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[8,2,8,3],[18,2,18,3],[19,2,19,3],[23,2,23,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910298267903321"]
[null,null,"Titolo",null,"Endocannabinoids / / edited by Roger G. Pertwee"]
[null,null,"Pubbl/distr/stampa",null,"Cham : , : Springer International Publishing : , : Imprint : Springer, , 2015"]
[null,null,"ISBN",null,"3-319-20825-X"]
[null,null,"Edizione",null,"[1st ed. 2015.]"]
[null,null,"Descrizione fisica",null,"1 online resource (477 p.)"]
[null,null,"Collana",null,"Handbook of Experimental Pharmacology, , 0171-2004 ; ; 231"]
[null,null,"Disciplina",null,"615.7827"]
[null,null,"Soggetti",null,"Pharmacology"]
[{"$nulls":4},"Cytology"]
[{"$nulls":4},"Neurosciences"]
[{"$nulls":4},"Psychopharmacology"]
[{"$nulls":4},"Immunology"]
[{"$nulls":4},"Cytokines"]
[{"$nulls":4},"Growth factors"]
[{"$nulls":4},"Pharmacology/Toxicology"]
[{"$nulls":4},"Cell Biology"]
[{"$nulls":4},"Cytokines and Growth Factors"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references at the end of each chapters and index."]
[null,null,"Nota di contenuto",null,"Preface; The Endocannabinoid System: A Look Back and Ahead; Contents; Endocannabinoids and Their Pharmacological Actions; 1 Introduction; 2 Evidence That Certain Endogenous Compounds Target Cannabinoid Receptors Orthosterically; 2.1 Evidence from Binding Assays; 2.2 Evidence from Two Functional Bioassays; 2.2.1 [35S]GTPgammaS Binding Assay; 2.2.2 Cyclic AMP Assay; 3 Non-Cannabinoid Receptors and Channels Targeted by Endogenous Cannabinoid Receptor Ligands at Submicromolar Concentrations; 3.1 Non-Cannabinoid G Protein-Coupled Receptors; 3.1.1 GPR55; 3.2 Ligand-Gated Ion Channels"]
[{"$nulls":4},"3.2.1 5-HT3 Receptors3.2.2 Nicotinic Acetylcholine Receptors; 3.2.3 Glycine Receptors; 3.2.4 Ionotropic Glutamate NMDA Receptors; 3.3 Transient Receptor Potential Channels; 3.3.1 TRPV1; 3.3.2 TRPM8 Channels; 3.4 Voltage-Gated Calcium Channels; 3.4.1 T-Type Cav3 Calcium Channels; 3.5 Potassium Channels; 3.5.1 ATP-Sensitive Inward Rectifier KATP Channels of the 2TM Domain Family; 3.5.2 Voltage-"]
[{"$nulls":4},"Gated Kv and KCa Channels of the 6TM Domain Family; 4 Allosteric Endocannabinoids; 5 Conclusions; References; Biosynthesis and Fate of Endocannabinoids"]
[{"$nulls":4},"1 Endocannabinoids and Endocannabinoid-Like Compounds2 Biosynthesis of the Endocannabinoids; 3 Uptake of the Endocannabinoids: Proposed Mechanisms; 4 Degradation of the Endocannabinoids; 4.1 FAAH and NAAA; 4.2 MGL, ABHD6 and ABHD12; 5 Conclusions; References; Distribution of the Endocannabinoid System in the Central Nervous System; 1 Introduction; 1.1 Overview; 1.2 Cells Expressing Components of the ECS; 1.3 Subcellular Localization of CB1 Cannabinoid Receptors; 2 Retina; 2.1 Receptors; 2.2 Synthetic Enzymes; 2.3 Degradative Enzymes; 3 Cerebral Cortex; 3.1 Neocortex; 3.1.1 Receptors"]
[{"$nulls":4},"3.1.2 Synthetic Enzymes3.1.3 Degradative Enzymes; 3.2 Olfactory Areas (Olfactory Bulb, Piriform Cortex, Associated Regions); 3.2.1 Receptors; 3.2.2 Synthetic Enzymes; 3.2.3 Degradative Enzymes; 3.3 Hippocampal Formation; 3.3.1 Receptors; 3.3.2 Synthetic Enzymes; 3.3.3 Degradative Enzymes; 3.4 Cortical Subplate (Other Amygdala Nuclei); 3.4.1 Receptors; 3.4.2 Synthetic Enzymes; 3.4.3 Degradative Enzymes; 4 Subcortical Nuclei (Striatum, Basal Ganglia); 4.1 Striatum (Dorsal, Caudate); 4.1.1 Receptors; 4.1.2 Synthetic Enzymes; 4.1.3 Degradative Enzymes; 4.2 Striatum (Ventral, Accumbens)"]
[{"$nulls":4},"4.2.1 Receptors4.2.2 Synthetic Enzymes; 4.2.3 Degradative Enzymes; 4.3 Striatum Medial (Lateral Septum, Septohippocampal, etc.); 4.3.1 Receptors; 4.3.2 Synthetic Enzymes; 4.3.3 Degradative Enzymes; 4.4 Striatum Caudal (Striatum-like Amygdala Nuclei, Central Amygdala, Bed Nucleus, Medial Amygdala, Etc.); 4.4.1 Receptors; 5 Cerebellum and Associated Nuclei; 5.1 Cerebellar Cortex; 5.1.1 Receptors; 5.1.2 Synthetic Enzymes; 5.1.3 Degradative Enzymes; 5.2 Deep Cerebellar Nuclei (Fastigial, Interpos, Dentate Nucleus); 5.2.1 Receptors; 5.2.2 Synthetic Enzymes; 5.2.3 Degradative Enzymes; 6 Brainstem"]
[{"$nulls":4},"6.1 Diencephalon"]
[null,null,null,"Sommario/riassunto","There is currently considerable interest in the development of medicines that would enhance endocannabinoid-induced “autoprotection”, for example through inhibition of endocannabinoid metabolizing enzymes or cellular uptake processes or that would oppose endocannabinoid-induced “autoimpairment”. This volume describes the physiology, pathophysiology and pharmacology of the endocannabinoid system and potential strategies for targeting this system in the clinic."]